A fusion polypeptide for use for inhibiting neovascularization, comprising: a peptide specifically binding to vascular endothelial growth factor (VEGF) receptors; and a hydrophilic elastin-based polypeptide (hydrophilic EBP) linked to the peptide, wherein the hydrophilic EBP is composed of an amino acid sequence represented by Formula 1 or 2 below: Formula 1 [SEQ ID NO: 1]n; or Formula 2 [SEQ ID NO: 2]n, wherein SEQ ID NO. 1 consists of [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG]; SEQ ID NO. 2 consists of [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG]; wherein n is an integer of 1 or more, and represents the number of repeats of SEQ ID NO: 1 or SEQ ID NO: 2; wherein in Formula 1, n is 1, and each X of the pentapeptide VPGXG repeats consists of, A (Ala), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 20]; K (Lys), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 22]; D (Asp), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 24]; or E (Glu), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 26], or in Formula 2, n is 1, and each X of the pentapeptide VPAXG repeats consists of, A (Ala), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 21]; K (Lys), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 23]; D (Asp), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 25]; or E (Glu), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 27], or in Formula 2, n is 3, 6, 12 or 24, and the pentapeptide VPAXG repeats correspond to SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43 or SEQ ID NO: 44 and each X of the pentapeptide VPAXG repeats consists of A (Ala), G (Gly), and I (Ile) in a ratio of 1:4:1, or in Formula 2, n is 12, and the pentapeptide VPAXG repeats correspond to [SEQ ID NO: 45] and each X of the pentapeptide VPAXG repeats consists of E (Glu), G (Gly), and I (Ile) in a ratio of 1:4:1. a peptide specifically binding to vascular endothelial growth factor (VEGF) receptors; and a hydrophilic elastin-based polypeptide (hydrophilic EBP) linked to the peptide, wherein the hydrophilic EBP is composed of an amino acid sequence represented by Formula 1 or 2 below: Formula 1 [SEQ ID NO: 1]n; or Formula 2 [SEQ ID NO: 2]n, wherein SEQ ID NO. 1 consists of [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG]; SEQ ID NO. 2 consists of [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG]; wherein n is an integer of 1 or more, and represents the number of repeats of SEQ ID NO: 1 or SEQ ID NO: 2; wherein in Formula 1, n is 1, and each X of the pentapeptide VPGXG repeats consists of, A (Ala), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 20]; K (Lys), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 22]; D (Asp), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 24]; or E (Glu), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 26], or in Formula 2, n is 1, and each X of the pentapeptide VPAXG repeats consists of, A (Ala), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 21]; K (Lys), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 23]; D (Asp), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 25]; or E (Glu), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 27], or in Formula 2, n is 3, 6, 12 or 24, and the pentapeptide VPAXG repeats correspond to SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43 or SEQ ID NO: 44 and each X of the pentapeptide VPAXG repeats consists of A (Ala), G (Gly), and I (Ile) in a ratio of 1:4:1, or in Formula 2, n is 12, and the pentapeptide VPAXG repeats correspond to [SEQ ID NO: 45] and each X of the pentapeptide VPAXG repeats consists of E (Glu), G (Gly), and I (Ile) in a ratio of 1:4:1. SEQ ID NO. 1 consists of [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG]; SEQ ID NO. 2 consists of [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG]; wherein n is an integer of 1 or more, and represents the number of repeats of SEQ ID NO: 1 or SEQ ID NO: 2; wherein in Formula 1, n is 1, and each X of the pentapeptide VPGXG repeats consists of, A (Ala), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 20]; K (Lys), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 22]; D (Asp), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 24]; or E (Glu), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 26], or in Formula 2, n is 1, and each X of the pentapeptide VPAXG repeats consists of, A (Ala), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 21]; K (Lys), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 23]; D (Asp), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 25]; or E (Glu), G (Gly), and I (Ile) in a ratio of 1:4:1 [SEQ ID NO: 27], or in Formula 2, n is 3, 6, 12 or 24, and the pentapeptide VPAXG repeats correspond to SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43 or SEQ ID NO: 44 and each X of the pentapeptide VPAXG repeats consists of A (Ala), G (Gly), and I (Ile) in a ratio of 1:4:1, or in Formula 2, n is 12, and the pentapeptide VPAXG repeats correspond to [SEQ ID NO: 45] and each X of the pentapeptide VPAXG repeats consists of E (Glu), G (Gly), and I (Ile) in a ratio of 1:4:1.